Related Experiment Video
Updated: Jan 15, 2026
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
Design synthesis and biological evaluation of novel BCL6/GSPT1 degrader as anti-DLBCL agent
Rong Hu1, Xia-Tong Hu2, Ying-Yue Yang2
1Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Abstract:
BCL6 is regarded as a promising therapeutic target for diffuse large B-cell lymphoma. However, most of the current BCL6 inhibitors and degraders have demonstrated limited antitumor efficacy when used as monotherapy. We hypothesized that developing multitarget degraders capable of simultaneously degrading multiple lymphoma-driving proteins might yield superior anti lymphoma activity. In this study, based on the BCL6 inhibitor BI3812, we designed and identified a dual-target degrader A5, which effectively degraded both BCL6 and GSPT1. A5 induced the degradation of BCL6 and GSPT1 in a time- and concentration-dependent manner, restored the expression of BCL6-regulated genes, and significantly promoted DNA damage in Farage cells. Consequently, A5 exhibited enhanced antiproliferative activity compared to the BCL6 inhibitor BI3812 and the BCL6 degrader BI3802, along with induction of cell cycle arrest and apoptosis. Furthermore, A5 significantly downregulated BCL6 and GSPT1 protein levels in vivo. Thus, this study provides a solid foundation for the development of novel multitarget BCL6 degraders with improved anti-lymphoma potential.
Insights
This study introduces A5, a novel dual-target degrader that effectively degrades both BCL6 and GSPT1 proteins. This multitarget approach shows enhanced anti-lymphoma activity compared to single-target therapies.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- BCL6 is a key therapeutic target in diffuse large B-cell lymphoma (DLBCL).
- Current BCL6 inhibitors and degraders show limited efficacy as monotherapy for DLBCL.
- Developing multitarget degraders may overcome limitations of single-target agents.
Purpose of the Study:
- To design and identify a dual-target degrader targeting both BCL6 and GSPT1.
- To evaluate the anti-lymphoma activity of the novel dual-target degrader A5.
- To assess the in vitro and in vivo efficacy of A5 in DLBCL models.
Main Methods:
- Design of a dual-target degrader (A5) based on a BCL6 inhibitor (BI3812).
- Assessment of BCL6 and GSPT1 degradation in DLBCL cell lines (Farage cells).
- Evaluation of A5's effect on gene expression, DNA damage, cell cycle, apoptosis, and in vivo protein levels.
Main Results:
- A5 effectively induced time- and concentration-dependent degradation of BCL6 and GSPT1.
- A5 restored BCL6-regulated gene expression and promoted DNA damage.
- A5 demonstrated superior antiproliferative activity, cell cycle arrest, and apoptosis induction compared to single-target agents.
- A5 significantly downregulated BCL6 and GSPT1 protein levels in vivo.
Conclusions:
- Dual-target degrader A5 exhibits enhanced anti-lymphoma activity by simultaneously degrading BCL6 and GSPT1.
- A5 represents a promising strategy for developing novel multitarget degraders for DLBCL.
- This study lays the groundwork for improved therapeutic approaches in lymphoma treatment.
